Chemomab Therapeutics Ltd.

CMMB · Nasdaq · SIC 2834: Pharmaceutical Preparations
142
SEC Filings

Business Summary

Overview Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory di...

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCMMBdiscussed_in_filing Trusted Computing
topic_mentionCMMBdiscussed_in_filing Blockchain & Crypto
topic_mentionCMMBdiscussed_in_filing Autonomous Vehicles
topic_mentionCMMBdiscussed_in_filing Regulation
topic_mentionCMMBdiscussed_in_filing Healthcare & Bio
topic_mentionCMMBdiscussed_in_filing Platform & Ecosystem
topic_mentionCMMBdiscussed_in_filing Trusted Computing
topic_mentionCMMBdiscussed_in_filing Blockchain & Crypto
topic_mentionCMMBdiscussed_in_filing Autonomous Vehicles
topic_mentionCMMBdiscussed_in_filing Regulation
topic_mentionCMMBdiscussed_in_filing Healthcare & Bio
topic_mentionCMMBdiscussed_in_filing Platform & Ecosystem
topic_mentionCMMBdiscussed_in_filing Trusted Computing
topic_mentionCMMBdiscussed_in_filing Blockchain & Crypto
topic_mentionCMMBdiscussed_in_filing Autonomous Vehicles
topic_mentionCMMBdiscussed_in_filing Regulation
topic_mentionCMMBdiscussed_in_filing Healthcare & Bio
topic_mentionCMMBdiscussed_in_filing Platform & Ecosystem
topic_mentionCMMBdiscussed_in_filing Trusted Computing
topic_mentionCMMBdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2023-03-202022-12-310001178913-23-001041EDGAR80K words
2022-03-302021-12-310001178913-22-001304EDGAR—
2021-03-092020-12-310001104659-21-033822EDGAR—
2020-03-172019-12-310001104659-20-034835EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2023-05-112023-03-310001178913-23-001807EDGAR10K words
2022-11-102022-09-300001178913-22-003931EDGAR—
2022-08-122022-06-300001178913-22-003074EDGAR—
2022-05-122022-03-310001178913-22-001919EDGAR—
2021-11-122021-09-300001178913-21-003509EDGAR—
2021-08-132021-06-300001178913-21-002696EDGAR—
2021-05-132021-03-310001104659-21-065588EDGAR—
2020-11-162020-09-300001104659-20-125523EDGAR—
2020-08-142020-06-300001104659-20-095149EDGAR—
2020-05-072020-03-310001104659-20-058143EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2023-06-160001178913-23-002225EDGAR1K words
2023-06-050001178913-23-002136EDGAR—
2023-05-110001178913-23-001809EDGAR—
2023-02-210001178913-23-000679EDGAR—
2023-02-210001178913-23-000670EDGAR—
2023-01-110001178913-23-000147EDGAR—
2023-01-030001178913-23-000010EDGAR—
2022-11-160001178913-22-004061EDGAR—
2022-11-140001178913-22-004019EDGAR—
2022-08-120001178913-22-003072EDGAR—

142 total filings indexed. 118 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001534248
TickerCMMB
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedL3

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e68f39d82ecd82e5a801acc00cb8bbf426883db534d3695fe8b03419f3bf126e
parent: d1bd1ec98871afa1908a90060f11881a9623b0fcc4821b3d15d3dcf838dcb2cd
content hash: d8b9afebb7f4cb6c1586081225d885f26258b0eb896a255e4fe4ba4454d40298
signed: 2026-04-13T04:44:23.425Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf